医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Hitachi Medical Announces Release of New Evolution 5 MRI Software Platform

2015年11月23日 PM10:42
このエントリーをはてなブックマークに追加


 

CLEVELAND

In conjunction with the upcoming RSNA 2015 exhibition, Hitachi Medical Systems America, Inc. (HMSA) announced the availability of their new MRI software platform “Evolution 5” available for current Hitachi customers and new system orders. The release of Evolution 5 is a notable milestone with nearly forty (40) new features and improvements implemented that continue to raise the level of imaging performance and quality, while simultaneously growing the breadth of applications available for diagnostic evaluation.

With the integration of a new image processing algorithm (VIVID), new reconstruction task (NCC) that reduces redundant noise pickup, and new optimized FSE sequence (opFSE), customers that migrate to Evolution 5 will see the difference with dramatically improved sharpness and clarity. The resulting images show greater overall uniformity and contrast, enabling better readability and clinical insight.

In addition, HMSA continues the expansion of their portfolio of applications including

  • Motion Compensation with the most complete neuro suite “All Around RADAR”
  • Selective Saturation for controlled MRA evaluation in the abdomen
  • Diffusion with enhanced functional analysis including kurtosis imaging (DKI)
  • Liver Imaging with iron quantification
  • Breast Imaging with Breast Spectroscopy for therapy monitoring

Sheldon Schaffer, General Manager and Vice President of the MR and CT business units commented, “Evolution 5 represents one of the most significant software releases for our MR platforms. As we look to expand our services to major regional hospitals and national health systems, Evolution 5 offers diagnostic capabilities which will give these customers a new choice among high-performance MR imaging systems.”

Evolution 5 is available now on the Echelon Oval 1.5T (the widest wide-bore in the industry), with new shipments and no charge software upgrades for customers under warranty or service maintenance agreement beginning January 1, 2016, with availability on Hitachi Medical’s other leading MRI products, including the Oasis 1.2T Open High-Field and Trillium Oval 3T systems, expected to follow later in the year.

About Hitachi Medical Systems America, Inc.

Hitachi Medical Systems America, Inc. (HMSA) located in Twinsburg, Ohio, a wholly owned subsidiary of Hitachi Medical Corporation offers a broad range of diagnostic imaging equipment including MRI, CT and Ultrasound. Our innovations in diagnostic imaging provide technology that drives clinical solutions to deliver diagnostic confidence, improve workflow efficiency and provide a better patient experience. In addition to exceptional equipment, HMSA is known for its comprehensive customer support programs to maximize the lifecycle value of equipment through responsive service maintenance, significant software upgrades and on-going applications support.

About Hitachi, Ltd.

Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges with our talented team and proven experience in global markets. The company’s consolidated revenues for fiscal 2013 (ended March 31, 2014) totaled 9,616 billion yen ($93.4 billion). Hitachi is focusing more than ever on the Social Innovation Business, which includes infrastructure systems, information & telecommunication systems, power systems, construction machinery, high functional material & components, automotive systems, health care and others. For more information on Hitachi, please visit the company’s website at http://www.hitachi.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151123005648/en/

CONTACT

Hitachi Medical Systems America, Inc.
Raymond Wtulich, 800-800-3106
ext. 2616
Wtulichr@hitachimed.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • FDA Grants Priority Review for Genentech’s Actemra® (Tocilizumab) Supplemental Biologics License Application for Giant Cell Arteritis, a Form of Vasculitis
  • TL PLASTIC SURGERY in South Korea, the Best Choice for Your Satisfying Breast Augmentation Surgery
  • Ascendia Pharmaceuticals宣布其治疗急性冠脉综合征的ASD-002项目获颁一项新专利
  • 年次世界患者安全・科学・技術サミットで初めて米国外向けにHDライブストリーミングを実施へ
  • Accelsiors CRO Expands Global Footprint